Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
:GSK
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.72 - $44.67
Previous CloseN/A
Volume981.79K
Average Volume (3M)4.79M
Market Cap
$81.64B
Enterprise Value$134.22B
Total Cash (Recent Filing)$4.49B
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)20.8
Beta0.28
Next Earnings
Jul 30, 2025EPS Estimate
1.16Last Dividend Ex-Date
May 16, 2025Dividend Yield4.2%
Share Statistics
EPS (TTM)1.20
Shares Outstanding2,047,178,100
10 Day Avg. Volume4,488,327
30 Day Avg. Volume4,786,353
Financial Highlights & Ratios
PEG Ratio-2.17
Price to Book (P/B)11.04
Price to Sales (P/S)0.00
P/FCF Ratio22.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$40.42Price Target Upside-0.17% Downside
Rating ConsensusHold
Number of Analyst Covering3
GlaxoSmithKline News
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of efimosfermin is sound given that it expands GSK's hepatology portfolio, provides optionality to related diseases, and fits within GSK's BD strategy.
Clinical DevelopmentGSK's press release characterized the clinical profile of efimosfermin as 'potential best in class' based upon unique properties such as low immunogenicity and extended half-life.
Market DominanceThe RSV market would be a 2-company market dominated by GSK and Pfizer.
Bears Say
Manufacturing ComplexityGSK noted the manufacturing for Trelegy is even more complicated than those devices, which suggests a competitive advantage.
Ownership Overview
―
Insiders
6.31% Mutual Funds
10.39% Other Institutional Investors
83.03% Public Companies and Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was $31.71 and its highest was $44.67 in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is $81.64B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Jul 30, 2025 which is in 43 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Apr 30, 2025. The company reported $1.199 earnings per share for the quarter, beating the consensus estimate of $1.045 by $0.154.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Overvalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of $1.573 which represents an annual dividend yield of 4.2%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 1.16.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 2,047,178,100 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of $1.199 in its last earnings report, beating expectations of $1.045. Following the earnings report the stock price went up 2.258%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GSK
GlaxoSmithKline Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$40.42 (-0.17% Downside)
$40.42 (-0.17% Downside)
Blogger Sentiment
Bullish
GSK Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 19.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.89%
12-Months-Change
Fundamentals
Return on Equity
22.26%
Trailing 12-Months
Asset Growth
6.01%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
GSK Company Deck
GSK Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in specialty medicines and promising R&D advancements, positioning GSK for continued success. However, challenges such as declining vaccine sales, macroeconomic uncertainties, and impacts from Medicare Part D redesign were notable concerns. Despite these issues, the overall sentiment remains positive due to strategic growth areas and confident long-term outlooks.Read More>GSK Stock 12 Month Forecast
Average Price Target
$40.42
▼(-0.17%Downside)